Free Trial
NASDAQ:BCYC

Bicycle Therapeutics (BCYC) Stock Price, News & Analysis

Bicycle Therapeutics logo
$7.90 -0.10 (-1.19%)
As of 10:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Bicycle Therapeutics Stock (NASDAQ:BCYC)

Key Stats

Today's Range
$7.86
$8.01
50-Day Range
$6.95
$9.30
52-Week Range
$6.10
$28.67
Volume
9,954 shs
Average Volume
396,121 shs
Market Capitalization
$547.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Moderate Buy

Company Overview

Bicycle Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

BCYC MarketRank™: 

Bicycle Therapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 233rd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bicycle Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bicycle Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bicycle Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($3.06) to ($3.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bicycle Therapeutics is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bicycle Therapeutics is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bicycle Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Bicycle Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    4.64% of the float of Bicycle Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bicycle Therapeutics has a short interest ratio ("days to cover") of 7.1.
  • Change versus previous month

    Short interest in Bicycle Therapeutics has recently decreased by 28.12%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Bicycle Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Bicycle Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.64% of the float of Bicycle Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bicycle Therapeutics has a short interest ratio ("days to cover") of 7.1.
  • Change versus previous month

    Short interest in Bicycle Therapeutics has recently decreased by 28.12%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Bicycle Therapeutics has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Bicycle Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    2 people have searched for BCYC on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $58,820.00 in company stock.

  • Percentage Held by Insiders

    22.90% of the stock of Bicycle Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bicycle Therapeutics' insider trading history.
Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Stock News Headlines

Bicycle Therapeutics plc (BCYC) - Yahoo Finance
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

BCYC Stock Analysis - Frequently Asked Questions

Bicycle Therapeutics' stock was trading at $14.00 at the start of the year. Since then, BCYC shares have decreased by 43.5% and is now trading at $7.9050.

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) released its quarterly earnings results on Thursday, May, 1st. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by $0.02. The company earned $9.98 million during the quarter, compared to the consensus estimate of $8.67 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 25.54% and a negative net margin of 790.07%.

Bicycle Therapeutics (BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Top institutional shareholders of Bicycle Therapeutics include Harbor Capital Advisors Inc. (0.20%). Insiders that own company stock include Bros Advisors Lp Baker, Kevin Lee, Michael Skynner, Alistair Milnes, Santiago Arroyo, Nicholas Keen, Michael Charles Ferguso Hannay, Nigel Crockett, Alethia Young, Travis Alvin Thompson and Lee Kalowski.
View institutional ownership trends
.

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bicycle Therapeutics investors own include Vale (VALE), uniQure (QURE), Clean Energy Fuels (CLNE), Paycom Software (PAYC), Grayscale Ethereum Trust (ETH) (ETHE), Curaleaf (CURLF) and Marathon Oil (MRO).

Company Calendar

Last Earnings
5/01/2025
Today
7/10/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCYC
CIK
1761612
Fax
N/A
Employees
240
Year Founded
N/A

Price Target and Rating

High Price Target
$48.00
Low Price Target
$14.00
Potential Upside/Downside
+212.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$169.03 million
Net Margins
-790.07%
Pretax Margin
-811.46%

Debt

Sales & Book Value

Annual Sales
$35.28 million
Price / Cash Flow
N/A
Book Value
$11.48 per share
Price / Book
0.70

Miscellaneous

Free Float
53,395,000
Market Cap
$554 million
Optionable
Optionable
Beta
1.41
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:BCYC) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners